3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
5
Recruiting
2
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Oxaliplatin
6
tislelizumab
3
Irinotecan
3
Fluorouracil
3
Chemotherapy, Adjuvant
3
Capecitabine
3
sintilimab
2
raltitrexed
2
pembrolizumab
2
Surgical Procedures, Operative
2
Specimen Handling
2
Neoadjuvant Therapy
2
HMPL-013
2
spartalizumab
1
rimegepant sulfate
1
encorafenib
1
cemiplimab
1
balstilimab
1
XELOX
1
Surgical Fixation Devices
1
Radiofrequency Ablation
1
Propranolol
1
Preoperative Exercise
1
Pemetrexed
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mortality
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Laparoscopy
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Colonic Neoplasms
×
encorafenib
×
Clear all
NCT07178717
2025-09-17
REFISH
Vall d'Hebron Institute of Oncology
Phase 2
Not yet recruiting
25 enrolled